186 related articles for article (PubMed ID: 32576028)
21. Refining the management of relapsed or refractory follicular lymphoma.
Pagel JM; Burke JM; Leslie LA
Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
[TBL] [Abstract][Full Text] [Related]
22. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Panayiotidis P; Follows GA; Mollica L; Nagler A; Özcan M; Santoro A; Stevens D; Trevarthen D; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL; Dreyling M
Blood Adv; 2021 Feb; 5(3):823-828. PubMed ID: 33560394
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Mensah FA; Blaize JP; Bryan LJ
Onco Targets Ther; 2018; 11():4817-4827. PubMed ID: 30147333
[TBL] [Abstract][Full Text] [Related]
26. Update on the role of copanlisib in hematologic malignancies.
Le T; Jerel D; Bryan LJ
Ther Adv Hematol; 2021; 12():20406207211006027. PubMed ID: 33889376
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
28. Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.
Chauhan AF; Cheson BD
Cancer Manag Res; 2021; 13():677-692. PubMed ID: 33531838
[TBL] [Abstract][Full Text] [Related]
29. PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.
Sapon-Cousineau V; Sapon-Cousineau S; Assouline S
Curr Treat Options Oncol; 2020 Apr; 21(6):51. PubMed ID: 32356174
[TBL] [Abstract][Full Text] [Related]
30. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
31. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Liu W; Ping L; Xie Y; Sun Y; Du T; Niu Y; Cisternas G; Huang F; Garcia-Vargas J; Childs BH; Mehra A; Reschke S; Wang X; Song Y; Zhu J
Cancer Chemother Pharmacol; 2022 Jun; 89(6):825-831. PubMed ID: 35322287
[TBL] [Abstract][Full Text] [Related]
32. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Chin CK; Nastoupil LJ
Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578
[TBL] [Abstract][Full Text] [Related]
33. The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma.
Schweitzer J; Hoffman M; Graf SA
Expert Opin Pharmacother; 2022 Apr; 23(5):535-541. PubMed ID: 35209784
[TBL] [Abstract][Full Text] [Related]
34. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
[TBL] [Abstract][Full Text] [Related]
36. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
Nastoupil LJ
Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
[TBL] [Abstract][Full Text] [Related]
37. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Morschhauser F; Machiels JP; Salles G; Rottey S; Rule SAJ; Cunningham D; Peyrade F; Fruchart C; Arkenau HT; Genvresse I; Liu L; Köchert K; Shen K; Kneip C; Peña CE; Grevel J; Zhang J; Cisternas G; Reschke S; Granvil C; Awada A
Mol Cancer Ther; 2020 Feb; 19(2):468-478. PubMed ID: 31619463
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapies for Follicular Lymphoma.
Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
[TBL] [Abstract][Full Text] [Related]
39. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Yhim HY; Kim T; Kim SJ; Shin HJ; Koh Y; Kim JS; Park J; Park GS; Kim WS; Moon JH; Yang DH
Ann Oncol; 2021 Apr; 32(4):552-559. PubMed ID: 33352201
[TBL] [Abstract][Full Text] [Related]
40. A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Doi T; Fuse N; Yoshino T; Kojima T; Bando H; Miyamoto H; Kaneko M; Osada M; Ohtsu A
Cancer Chemother Pharmacol; 2017 Jan; 79(1):89-98. PubMed ID: 27915408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]